BRICKELL BIOTECH INC (BBI) Stock Fundamental Analysis

NASDAQ:BBI • US10802T2042

2.35 USD
+0.05 (+2.17%)
Last: Sep 7, 2022, 08:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BBI scores 3 out of 10 in our fundamental rating. BBI was compared to 521 industry peers in the Biotechnology industry. BBI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BBI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • BBI had negative earnings in the past year.
BBI Yearly Net Income VS EBIT VS OCF VS FCFBBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -191.83%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBI Yearly ROA, ROE, ROICBBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

  • BBI does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -8325.47%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBI Yearly Profit, Operating, Gross MarginsBBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • BBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BBI has less shares outstanding than it did 1 year ago.
  • There is no outstanding debt for BBI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBI Yearly Shares OutstandingBBI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
BBI Yearly Total Debt VS Total AssetsBBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

  • BBI has an Altman-Z score of -15.04. This is a bad value and indicates that BBI is not financially healthy and even has some risk of bankruptcy.
  • BBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.04
ROIC/WACCN/A
WACC9.67%
BBI Yearly LT Debt VS Equity VS FCFBBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 4.36 indicates that BBI has no problem at all paying its short term obligations.
  • BBI has a Quick Ratio of 4.36. This indicates that BBI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.36
Quick Ratio 4.36
BBI Yearly Current Assets VS Current LiabilitesBBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • BBI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1880.96%.
  • The Revenue for BBI has decreased by -40.13% in the past year. This is quite bad
  • The Revenue for BBI have been decreasing by -51.15% on average. This is quite bad
EPS 1Y (TTM)-1880.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)-40.12%
Revenue growth 3Y-37.06%
Revenue growth 5Y-51.15%
Sales Q2Q%360%

3.2 Future

  • Based on estimates for the next years, BBI will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.32% on average per year.
  • The Revenue is expected to grow by 67.18% on average over the next years. This is a very strong growth
EPS Next Y70.65%
EPS Next 2Y30.88%
EPS Next 3Y19.65%
EPS Next 5Y11.32%
Revenue Next Year1253.05%
Revenue Next 2Y295.6%
Revenue Next 3Y136.3%
Revenue Next 5Y67.18%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BBI Yearly Revenue VS EstimatesBBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
BBI Yearly EPS VS EstimatesBBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BBI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBI Price Earnings VS Forward Price EarningsBBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.27
BBI Per share dataBBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

  • BBI's earnings are expected to grow with 19.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.88%
EPS Next 3Y19.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BBI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BRICKELL BIOTECH INC

NASDAQ:BBI (9/7/2022, 8:17:32 PM)

2.35

+0.05 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11
Earnings (Next)11-07
Inst Owners0.22%
Inst Owner Change-87.67%
Ins Owners27.45%
Ins Owner Change0%
Market Cap6.23M
Revenue(TTM)479.00K
Net Income(TTM)-39.88M
Analysts82.5
Price Target18.19 (674.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.01
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB N/A
EV/EBITDA 0.27
EPS(TTM)-20.7
EYN/A
EPS(NY)-6.85
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.18
BVpS6.05
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -191.83%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -8325.47%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.36
Quick Ratio 4.36
Altman-Z -15.04
F-Score4
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1880.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y70.65%
EPS Next 2Y30.88%
EPS Next 3Y19.65%
EPS Next 5Y11.32%
Revenue 1Y (TTM)-40.12%
Revenue growth 3Y-37.06%
Revenue growth 5Y-51.15%
Sales Q2Q%360%
Revenue Next Year1253.05%
Revenue Next 2Y295.6%
Revenue Next 3Y136.3%
Revenue Next 5Y67.18%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BRICKELL BIOTECH INC / BBI FAQ

Can you provide the ChartMill fundamental rating for BRICKELL BIOTECH INC?

ChartMill assigns a fundamental rating of 3 / 10 to BBI.


What is the valuation status for BBI stock?

ChartMill assigns a valuation rating of 3 / 10 to BRICKELL BIOTECH INC (BBI). This can be considered as Overvalued.


What is the profitability of BBI stock?

BRICKELL BIOTECH INC (BBI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BBI stock?

The Earnings per Share (EPS) of BRICKELL BIOTECH INC (BBI) is expected to grow by 70.65% in the next year.